Sugi Predict

Sugi Predict / Compounds / SCHEMBL2702167

SCHEMBL2702167

SCHEMBL2702167

CCOc1ccc(Cl)cc1S(=O)(=O)Nc1ccc(C(=O)N2CCN(c3ccccc3OC)CC2)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.82
▸ HCRTR1 O43613 1/20 0.64
▸ MAPT P10636 4/20 0.62
▸ HTT P42858 2/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ LMNA P02545 5/20 0.54
▸ NPSR1 Q6W5P4 3/20 0.54
▸ NAMPT P43490 1/20 0.53
▸ REV1 Q9UBZ9 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ ALPL P05186 1/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ TSHR P16473 2/20 0.52
▸ GLA P06280 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ POLB P06746 3/20 0.52
▸ MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2701108 0.93 PKM (0.70) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL12964649 0.91 PKM (0.68) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL19036159 0.91 PKM (0.83) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL12964838 0.90 PKM (1.00) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL2704634 0.90 PKM (0.66) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL20035974 0.87 ALDH1A1 (0.67) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL28023291 0.86 PKM (0.61) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL26812005 0.85 HCRTR1 (0.75) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL16206627 0.84 PKM (0.58) PKMHCRTR1MAPTHTTALDH1A1
SCHEMBL12964577 0.83 ALDH1A1 (0.63) PKMMAPTHTTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428376-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20240360083-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2024-10-31 — — US disclosed
US-11866411-B2 Therapeutic compounds and compositions Agios Pharmaceutical, Inc. (US) 2024-01-09 — — US disclosed
US-RE49582-E1 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2023-07-18 — — US disclosed
US-20210198206-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2021-07-01 — — US disclosed
US-20210198206-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2021-07-01 — — US disclosed
US-10988448-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2021-04-27 — — US disclosed
US-10988448-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2021-04-27 — — US disclosed
EP-3708169-A1 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY Agios Pharmaceuticals, Inc. (US) 2020-09-16 — — EP disclosed
EP-3708169-A1 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY Agios Pharmaceuticals, Inc. (US) 2020-09-16 — — EP disclosed
EP-2448582-B1 QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY AGIOS PHARMACEUTICALS INC (US) 2017-04-19 — — EP disclosed
EP-2448582-B1 QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY AGIOS PHARMACEUTICALS INC (US) 2017-04-19 — — EP disclosed
CN-102481300-B Therapeutic compounds and compositions AGIOS PHARMACEUTICALS INC 2015-04-15 — — CN disclosed
US-20140323467-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC (US) 2014-10-30 — — US disclosed
US-8785450-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2014-07-22 — — US disclosed
US-8785450-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2014-07-22 — — US disclosed
EP-2448582-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Agios Pharmaceuticals, Inc. (US) 2012-05-09 — — EP disclosed
WO-2011002817-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. (US) 2011-01-06 — — WO disclosed
US-20100331307-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2010-12-30 — — US disclosed
US-20100331307-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2010-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10988448-B2 Therapeutic compounds and compositions PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-20210198206-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-12428376-B2 Therapeutic compounds and compositions PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-20240360083-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-20100331307-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-20140323467-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885
US-11866411-B2 Therapeutic compounds and compositions PDK1, PDK2, PDK3 PKM 6/4885HCRTR1 4844/4885MAPT 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.